Blar i forfatter Det helsevitenskapelige fakultet "Haugen, Mads"

Viser treff 1-2 av 2

    • High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer 

      Normann, Lisa Svartdal; Haugen, Mads; Hongisto, Vesa; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Kristensen, Vessela N.; Tahiri, Andliena; Engebråten, Olav; Sahlberg, Guro Kristine Kleivi; Mælandsmo, Gunhild Mari (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-27)
      Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic strategies as some patients respond poorly to treatment. Our aim was to identify compounds that substantially affect viability in HER2+ breast cancer cells in response to combinatorial treatment. We ...

    • Liver X receptors induce antiproliferative effects in basal-like breast cancer 

      Haugen, Mads; von der Lippe Gythfeldt, Hedda; Egeland, Eivind Valen; Svartdal Normann, Lisa; Pandya, Abhilash D.; Vedin, Lise-Lotte; Juell, Siri; Tenstad, Ellen; Øy, Geir Frode; Kristian, Alexandr; Marangoni, Elisabetta; Sørlie, Therese; Steffensen, Knut Rune; Mælandsmo, Gunhild Mari; Engebråten, Olav (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-21)
      Liver X receptors (LXRs) are nuclear transcription factors important in the regulation of cholesterol transport, and glucose and fatty acid metabolism. The antiproliferative role of LXRs has been studied in a variety of malignancies and may represent a therapeutic opportunity in cancers lacking targeted therapies, such as triple-negative breast cancer. In this study, we investigated the impact of ...